About
Tempest Therapeutics Inc (NASDAQ:TPST) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 22 2026
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
Apr 14 2026
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
Mar 30 2026
Tempest Reports Year End 2025 Financial Results and Provides Business Update
Mar 23 2026
Tempest Therapeutics Announces Up To $6 Million Private Placement
Mar 11 2026
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
Financials
Revenue
$0
Market Cap
$22.81 M
EPS
-6.33
Translate